» Articles » PMID: 34725309

Role of Tumor Necrosis Factor-α in the Mortality of Hospitalized Patients with Severe and Critical COVID-19 Pneumonia

Overview
Specialty Geriatrics
Date 2021 Nov 2
PMID 34725309
Citations 10
Authors
Affiliations
Soon will be listed here.
Abstract

The coronavirus disease 2019 (COVID-19) is presently the most pressing public health concern worldwide. Cytokine storm is an important factor leading to death of patients with COVID-19. This study aims to characterize serum cytokines of patients with severe or critical COVID-19. Clinical records were obtained from 149 patients who were tested at the Sino-French New City Branch of Tongji Hospital from 30 January to 30 March 2020. Data regarding the clinical features of the patients was collected and analyzed. Among the 149, 45 (30.2%) of them had severe conditions and 104 (69.8%) of that presented critical symptoms. In the meantime, 80 (53.7%) of that 149 died during hospitalization. Of all, male patients accounted for 94 (69.1%). Compared with patients in severe COVID-19, those who in critical COVID-19 had significantly higher levels of tumor necrosis factor-α (TNF-α), interleukin-6 (IL-6), IL-8, and IL-10. Moreover, the passed-away patients had considerably higher levels of TNF-α, IL-6, IL-8, and IL-10 than those survived from it. Regression analysis revealed that serum TNF-α level was an independent risk factor for the death of patient with severe conditions. Among the proinflammatory cytokines (IL-1β, TNF-α, IL-8, and IL-6) analyzed herein, TNF-α was seen as a risk factor for the death of patients with severe or critical COVID-19. This study suggests that anti-TNF-α treatment allows patients with severe or critical COVID-19 pneumonia to recover.

Citing Articles

The Importance of the Concentration of Selected Cytokines (IL-6, IL-10, IL-12, IL-15, TNF-α) and Inflammatory Markers (CRP, NLR, PLR, LMR, SII) in Predicting the Course of Rehabilitation for Patients after COVID-19 Infection.

Minko A, Turon-Skrzypinska A, Ryl A, Mankowska K, Cymbaluk-Ploska A, Rotter I Biomedicines. 2024; 12(9).

PMID: 39335569 PMC: 11429050. DOI: 10.3390/biomedicines12092055.


Clinical characteristics and microbial signatures in the lower airways of diabetic and nondiabetic patients with pneumonia.

Liu X, Zhao Q, He X, Min J, Yao R, Chen Z J Thorac Dis. 2024; 16(8):5262-5273.

PMID: 39268134 PMC: 11388247. DOI: 10.21037/jtd-24-490.


Involvement of NLRP3 Inflammasome in SARS-Cov-2-Induced Multiorgan Dysfunction in Patients with COVID-19: A Review of Molecular Mechanisms.

Babazadeh Z Tanaffos. 2023; 22(1):40-52.

PMID: 37920322 PMC: 10618576.


The Immunomodulatory Role of Cell-Free Approaches in SARS-CoV-2-Induced Cytokine Storm-A Powerful Therapeutic Tool for COVID-19 Patients.

Csobonyeiova M, Smolinska V, Harsanyi S, Ivantysyn M, Klein M Biomedicines. 2023; 11(6).

PMID: 37371831 PMC: 10295896. DOI: 10.3390/biomedicines11061736.


Serum IL-23, IL-10, and TNF-α predict in-hospital mortality in COVID-19 patients.

Smail S, Babaei E, Amin K, Abdulahad W Front Immunol. 2023; 14:1145840.

PMID: 37283736 PMC: 10239952. DOI: 10.3389/fimmu.2023.1145840.


References
1.
Lu R, Zhao X, Li J, Niu P, Yang B, Wu H . Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding. Lancet. 2020; 395(10224):565-574. PMC: 7159086. DOI: 10.1016/S0140-6736(20)30251-8. View

2.
Chen L, Zhang Z, Wei X, Cai Y, Yao W, Wang M . Association between cytokine profiles and lung injury in COVID-19 pneumonia. Respir Res. 2020; 21(1):201. PMC: 7389162. DOI: 10.1186/s12931-020-01465-2. View

3.
Xu Z, Shi L, Wang Y, Zhang J, Huang L, Zhang C . Pathological findings of COVID-19 associated with acute respiratory distress syndrome. Lancet Respir Med. 2020; 8(4):420-422. PMC: 7164771. DOI: 10.1016/S2213-2600(20)30076-X. View

4.
Cauchois R, Koubi M, Delarbre D, Manet C, Carvelli J, Blasco V . Early IL-1 receptor blockade in severe inflammatory respiratory failure complicating COVID-19. Proc Natl Acad Sci U S A. 2020; 117(32):18951-18953. PMC: 7430998. DOI: 10.1073/pnas.2009017117. View

5.
Yanik G, Hellerstedt B, Custer J, Hutchinson R, Kwon D, Ferrara J . Etanercept (Enbrel) administration for idiopathic pneumonia syndrome after allogeneic hematopoietic stem cell transplantation. Biol Blood Marrow Transplant. 2002; 8(7):395-400. DOI: 10.1053/bbmt.2002.v8.pm12171486. View